SEC Filing Analysis: Livelsberger Financial Advisory (13F-HR)

Executive Summary

• Trading Significance: Low
• Key Takeaway: Livelsberger Financial Advisory, a small investment advisory firm, filed its quarterly Form 13F-HR, disclosing $2,683,978 in assets under management across 6 equity positions as of September 30, 2025.
• Market Impact: Due to the small size of the filer's assets under management, this filing is not expected to have any material impact on the market or the individual securities held.

Filer Information

Field	Value
Company	Livelsberger Financial Advisory
CIK	0002015721
Type	Institutional Investment Manager
Location	Ashland, OH

Portfolio Holdings Summary (as of 2025-09-30)

Issuer	CUSIP	Shares	Market Value ($)
ABBVIE INC	00287Y109	4,580	1,060,475
APPLE INC	037833100	1,736	442,083
ABBOTT LABS	002824100	3,273	438,416
PARKER-HANNIFIN CORP	701094104	333	252,191
MICROSOFT CORP	594918104	480	248,805
EXXON MOBIL CORP	30231G102	2,146	242,008
Total			2,683,978

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The total reported assets of ~$2.7 million are insignificant in the context of the broader market. The positions in mega-cap stocks like Apple, Microsoft, and Exxon Mobil represent a minuscule fraction of their total market capitalization and daily trading volume. This filing is a standard regulatory disclosure and does not signal any market-moving activity.

Volume & Sentiment

• Expected Volume Impact: None. The filing reports historical positions and does not represent new trades.
• Sentiment Indicator: Neutral. This filing provides a snapshot of a small advisory firm's portfolio, which appears to be a standard long-term holding strategy in blue-chip companies. It does not provide a strong bullish or bearish signal for any specific stock.

Investment Insights

Portfolio Composition

• The portfolio is highly concentrated, with the top holding, AbbVie Inc., accounting for approximately 39.5% of the total reported value.
• The top three holdings (AbbVie, Apple, Abbott Labs) together constitute over 72% of the portfolio, indicating a high-conviction approach in a few select names.
• The holdings are primarily in established, large-cap companies across healthcare, technology, industrials, and energy sectors.

Key Takeaways

1. Routine Filing: This is a standard, mandatory quarterly report for a registered investment advisor.
2. Small Player: Livelsberger Financial Advisory operates with a small asset base, making its holdings informational for observing small-firm strategy but not for predicting market movements.
3. Concentrated Bets: The firm has a significant concentration in AbbVie, suggesting a strong bullish thesis on that particular healthcare stock relative to the rest of its portfolio.

Contextual Analysis

Filing Context

This Form 13F-HR is a snapshot of the firm's long equity positions at the end of the third quarter of 2025. It does not show short positions, cash, or other asset classes. The data is over 40 days old (from 2025-09-30 to 2025-10-14) and may not reflect the firm's current holdings.

Risk Assessment

Risk Level: Low (for the market)

Risk Factors

• The filing itself poses no risk to the market.
• For the filer, the high concentration in a few stocks, particularly AbbVie, represents a significant firm-specific risk. Poor performance in this single stock would heavily impact the portfolio's overall return.

Market Considerations

• This filing is a data point for institutional ownership but is too small to be a factor in institutional flow analysis for the securities mentioned.

---

IMPORTANT DISCLAIMER: This analysis is for informational purposes only and is not intended as investment advice. The information presented is based on publicly available SEC filings and should not be construed as a recommendation to buy, sell, or hold any securities. Past performance does not guarantee future results. All investments carry risk, including the potential loss of principal. Please consult with a qualified financial advisor before making any investment decisions.

Analysis generated on 2025-10-14 | Data source: SEC EDGAR